Poly(ADP-ribose) Polymerases
"Poly(ADP-ribose) Polymerases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE.
| Descriptor ID |
D011065
|
| MeSH Number(s) |
D08.811.913.400.725.115.690
|
| Concept/Terms |
Poly(ADP-ribose) Polymerases- Poly(ADP-ribose) Polymerases
- ADP-Ribosyltransferase (Polymerizing)
- Poly(ADP-ribose) Polymerase
- Poly ADP Ribose Polymerase
- Poly ADP Ribose Transferase
- Poly(ADP-Ribose) Transferase
- PARP Polymerase
- Polymerase, PARP
- Poly(ADPribose) Polymerase
- Poly ADP-Ribose Synthase
- Poly ADP Ribose Synthase
- Synthase, Poly ADP-Ribose
- Poly(ADPR) Polymerase
- Poly(ADP-Ribose) Synthase
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerases".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerases".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerases" by people in this website by year, and whether "Poly(ADP-ribose) Polymerases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerases" by people in Profiles.
-
PARP12-mediated ADP-ribosylation contributes to breast cancer cell fate by regulating AKT activation and DNA-damage response. Cell Mol Life Sci. 2025 Jan 23; 82(1):58.
-
XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition. Sci Rep. 2020 08 28; 10(1):14253.
-
Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers. Clin Cancer Res. 2018 12 15; 24(24):6459-6470.
-
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017 03 01; 28(3):505-511.
-
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016 08; 21(8):954-63.
-
17ß estradiol regulates adhesion molecule expression in mesangial cells during glomerulonephritis. Clin Immunol. 2015 Jul; 159(1):13-22.
-
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014; 24(1):15-28.
-
Differential regulation of cell death programs in males and females by Poly (ADP-Ribose) Polymerase-1 and 17ß estradiol. Cell Death Dis. 2013 Aug 08; 4:e758.
-
N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. Cancer Lett. 2010 Dec 08; 298(2):186-94.
-
Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation. J Immunol. 2009 Jun 01; 182(11):7297-306.